We are monitoring the impact of COVID-19 on Europe Diabetic Retinopathy Market Get in touch with us for detailed analysis Know More
Pulished Date August, 2019
ID: 877
Share on
Share on

Europe Diabetic Retinopathy Market Research Report - Segmented By Treatment Type, Indication, End User, By Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis on Size, Share, Trends, Forecast, Growth | 2019 - 2024

Pulished: August, 2019
ID: 877
Pages: 143

The size of the European Diabetic Retinopathy Market has been estimated at USD 1.26 billion in 2019. It is projected to reach USD 1.73 billion by 2024, at a CAGR of 6.55% during the forecast period.

Diabetic retinopathy is a medical condition which damages the retina and leads to blindness if untreated or undiagnosed. The degree of treatment of diabetic retinopathy varies according to various stages of the disease and is mainly prioritized to curb the epidemic at its initial stage.

Growth enhancing factors are government initiatives, abundant R&D activities, and skill set enhancement of healthcare providers. Such supportive initiatives, coupled with rising awareness among patients, are anticipated to result in lucrative growth. Treatment of diabetic retinopathy is expected to gain patients' willingness for treatment by introducing advanced technology and reducing pain by using laser procedure with quick recovery time.

The adoption of sedentary lifestyles and changes in food habits is driving the demand of the market. An increasing number of diabetic patients is also considered to be a significant factor propelling the growth of the Europe diabetic retinopathy market. Growing awareness over the availability of drugs for different diseases is accelerating the demand of the market. The rise in the geriatric population and increasing incidences of blindness due to damage of blood vessels in the retina is gearing up the need of the market. Also, the growing number of surgical treatment procedures is prompting the growth of this market in Europe.

Growth opportunities for the market lie in the emergence of the latest technological developments and the introduction of innovative devices in favour of the end-user. Increasing concern towards health among individuals and the rise in the knowledge over the treatment procedures and also the availability of trained physicians are leveraging the growth of the market. Furthermore, increasing the constructional activities of hospitals with the latest equipment is fueling the demand of the market.

However, fluctuations in the production rate of the devices in the medical sector and the cost of installation and maintenance of the equipment is a bit expensive are slowly hampering the growth of the diabetic retinopathy market.  Stringent rules and regulations by the government in approving new products has remained a challenging factor for the market.

Regional Analysis

Based on Region, the European diabetic retinopathy market holds the highest share in the market, driven by rising patient awareness levels, particularly in the Western European countries. Increasing support from the government through investments is merely magnifying the growth rate of the UK diabetic retinopathy market.

Increasing incidences of obesity and cardiovascular problems in many people due to their lifestyle are lavishing the diabetic retinopathy market in Spain. The rise in the funds from both private and public organizations is gearing up the growth rate in the Spain market.

Ongoing research in the biotechnology field is ascribed to bolster the demand of the German diabetic retinopathy market. Growing priority for laser treatment surgeries is also broadening the need of the market in Germany.

Growing demand for low cost and secure operative surgical procedures is rising the need for diabetic retinopathy in Italy.

People's interest in healthy lifestyles and increasing demand for early diagnosis to have a permanent cure of the diseases is accelerating the diabetic retinopathy market in France enormously.

Leading companies in the Europe Diabetic Retinopathy Market profiled in the report are Bayer AG, Pfizer Inc., Hoffmann-La Roche ltd., Regeneron Pharmaceutical Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc. and Ampio Pharmaceuticals Inc.

This research report has been segmented and sub-segmented into the following categories:

By Treatment Type:

  • Anti-Vascular Endothelial Growth Factor (VEGF) drug
  • Intraocular Steroid Injection
  • Laser Surgery
  • Vitrectomy     

By Indication:

  • Non-Proliferative Diabetic Retinopathy (NPDR)
    • Mild
    • Moderate
    • Severe
  • Proliferative Diabetic Retinopathy (PDR) 

By End-User:

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                      

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                      

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                               

5. Market Segmentation                                                              

                5.1 By Type of Treatment                                            

                                5.1.1 Anti-Vascular Endothelial Growth Factor (VEGF) drug                          

                                5.1.2 Intraocular Steroid Injection                           

                                5.1.3 Laser Surgery                         

                                5.1.4 Vitrectomy                             

                5.2 By Indication                                              

                                5.2.1 Non-Proliferative Diabetic Retinopathy (NPDR)                      

                                                5.2.1.1 Mild       

                                                5.2.1.2 Moderate            

                                                5.2.1.3 Severe  

                                5.2.2 Proliferative Diabetic Retinopathy (PDR)                    

                5.3 By End Users                                             

                                5.3.1 Hospitals                  

                                5.3.2 Ophthalmic Clinics                               

                                5.3.3 Ambulatory Surgical Centers                           

6. Geographical Analysis                                                              

                                6.1 Introduction                              

                                6.2 U.K                

                                6.3 Spain                             

                                6.4 Germany                     

                                6.5 Italy                               

                                6.6 France                          

7. Strategic Analysis                                                       

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                      

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services               

                                7.2.5 Competitive Rivalry within the Industry                      

8. Market Leaders' Analysis                                                        

                8.1 Bayer AG                                     

                                8.1.1 Overview                

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                            

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Pfizer Inc.                                    

                8.3 Hoffmann-La Roche ltd                                          

                8.4 Regeneron Pharmaceutical Inc.                                         

                8.5 Novartis AG                                

                8.6 Valeant Pharmaceutical International Inc.                                     

                8.7 Abbott Laboratories Inc.                                       

                8.8 Alimera Science Inc.                                                

                8.9 Ampio Pharmaceuticals Inc.                                

9. Competitive Landscape                                                           

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                        

                9.3 Agreements, collaborations and Joint Ventures                                          

                9.4 New Product Launches                                          

10. Expert Opinions                                                        

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

Appendix                                                           

                a) List of Tables                                

                b) List of Figures                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Diabetic Retinopathy Market By Region, From 2019-2024 (USD Billion)
  2. Europe Diabetic Retinopathy Market By Treatment Type, From 2019-2024 (USD Billion)
  3. Europe Anti-Vascular Endothelial Growth Factor (VEGF) drug Market By Region, From 2019-2024 (USD Billion)
  4. Europe Intraocular Steroid Injection Market By Region, From 2019-2024 (USD Billion)
  5. Europe Laser Surgery Market By Region, From 2019-2024 (USD Billion)
  6. Europe Vitrectomy Market By Region, From 2019-2024 (USD Billion)
  7. Europe Diabetic Retinopathy Market By Indication, From 2019-2024 (USD Billion)
  8. Europe Non-Proliferative Diabetic Retinopathy (NPDR) Market By Region, From 2019-2024 (USD Billion)
  9. Europe Diabetic Retinopathy Market By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2019-2024 (USD Billion)
  10. Europe Mild Indication Market By Region, From 2019-2024 (USD Billion)
  11. Europe Moderate Indication Market By Region, From 2019-2024 (USD Billion)
  12. Europe Severe Indication Market By Region, From 2019-2024 (USD Billion)
  13. Europe Proliferative Diabetic Retinopathy (PDR) Market By Region, From 2019-2024 (USD Billion)
  14. Europe Diabetic Retinopathy Market By End Users, From 2019-2024 (USD Billion)
  15. Europe Hospitals Market By Region, From 2019-2024 (USD Billion)
  16. Europe Ophthalmic Clinics Market By Region, From 2019-2024 (USD Billion)
  17. Europe Ambulatory Surgical Centers Market By Region, From 2019-2024 (USD Billion)
  18. U.K Diabetic Retinopathy Market By Treatment Type, From 2019-2024 (USD Billion)
  19. U.K Diabetic Retinopathy Market By Indication, From 2019-2024 (USD Billion)
  20. U.K Diabetic Retinopathy Market By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2019-2024 (USD Billion)
  21. U.K Diabetic Retinopathy Market By End Users, From 2019-2024 (USD Billion)
  22. Spain Diabetic Retinopathy Market By Treatment Type, From 2019-2024 (USD Billion)
  23. Spain Diabetic Retinopathy Market By Indication, From 2019-2024 (USD Billion)
  24. Spain Diabetic Retinopathy Market By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2019-2024 (USD Billion)
  25. Spain Diabetic Retinopathy Market By End Users, From 2019-2024 (USD Billion)
  26. Germany Diabetic Retinopathy Market By Treatment Type, From 2019-2024 (USD Billion)
  27. Germany Diabetic Retinopathy Market By Indication, From 2019-2024 (USD Billion)
  28. Germany Diabetic Retinopathy Market By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2019-2024 (USD Billion)
  29. Germany Diabetic Retinopathy Market By End Users, From 2019-2024 (USD Billion)
  30. Italy Diabetic Retinopathy Market By Treatment Type, From 2019-2024 (USD Billion)
  31. Italy Diabetic Retinopathy Market By Indication, From 2019-2024 (USD Billion)
  32. Italy Diabetic Retinopathy Market By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2019-2024 (USD Billion)
  33. Italy Diabetic Retinopathy Market By End Users, From 2019-2024 (USD Billion)
  34. France Diabetic Retinopathy Market By Treatment Type, From 2019-2024 (USD Billion)
  35. France Diabetic Retinopathy Market By Indication, From 2019-2024 (USD Billion)
  36. France Diabetic Retinopathy Market By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2019-2024 (USD Billion)
  37. France Diabetic Retinopathy Market By End Users, From 2019-2024 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample